SummaryIn the present study based on clinical case reports, twelve dogs (7 males, 5 females) between the ages of 5 and 11 years old, with clinically diagnosed osteoarthritis of the elbow joint were undertaken for comparison of the therapeutic effect derived from the standard non-steroidal antiinflammatory drug (NSAIDs) treatment with novel, autologous adipose-derived mesenchymal stem cell (AdMSCs) application. Animals were not under any treatment for 3 last months before the diagnosis. Individuals from experimental group were treated with autologous adipose-derived mesenchymal stem cells, while individuals from control group received Mavacoxib (Trocoxil). After 0, 60, 90 and 180 days of the treatment, all individuals were clinically evaluated. Additionally, examination of synovial fluid from all of the animals was performed after 0, 60, 90 and 180 days. The CT analysis were performed at day 0 and 180 days after the treatment. The AdMSCs therapy in the case of elbow joint degeneration (OA) decreased the discomfort and reduced accompanying clinical symptoms like pain, stiffness when walking and lameness. In contrast, though the animals from control group showed the improvement during first period of experiment, the OA symptoms reoccurred 90 days after the application of NSAIDs. This work is the first report that not only describes the picture of clinical examination, but is also based on synovial fluid analysis and CT evaluation. The injections of autologous stem cells did not exhibit any adverse reactions, which confirms the safety of this method. Our research confirmed the efficiency of AdMSC injections for the treatment of elbow joint osteoarthritis in dogs, which improve the clinical picture and the patients' condition, however without the regresses of osteofites.
Keywords: Adipose-derived mesenchymal stem cells, Canine, Elbow joint diseases, Osteoarthritis
Köpeklerde Dejeneratif Dirsek Eklemi Bozukluğu Tedavisinde Non-steroidal Antiinflamatuar Ajan (NSAIA) Uygulanmasından Sonra Adipoz Doku Kökenli Otolog Mezenkimal Kök Hücrelerin (ADkOMKH) Faydası -Oniki Olgu
ÖzetBu çalışma klinik olarak dirsek ekleminde osteoartritis tespit edilen, standart non-steroidal anti inflammatuar ilaçlardan (NSAIA) türetilmiş terapötik ilaçla tedavi edilen 5-11 yaş arasında, oniki (7 erkek, 5 dişi) köpekte, adipoz doku orijinli otolog mezenkimal kök hücrelerin (ADkOMKH) etkinliğini karşılaştırmak için yapılmıştır. Teşhisten önce hayvanlara 3 ay boyunca herhangi bir uygulama yapılmamıştır. Deneysel gruptaki bireyler adipoz kökenli otolog mezenkimal kök hücrelerle tedavi edildi, buna karşın kontrol grubun bireylerine Mavacoxib (Trocoxil) uygulandı. Uygulamanın 0, 60, 90 ve 180. günlerinde, her bir birey klinik olarak muayene edildi. Ayrıca, tüm hayvanlardan 0, 60, 90 ve 180. günlerde ilgili eklemlerden alınan siynovial sıvıların analizi yapıldı. Ayrıca, 0 ve 180. günlerde CT analizi yapıldı. Dirsek eklemi dejenerasyonunda (OA); ADkOMKH ile tedaviye alınan hayvanlarda; ağrı, yürürken oluşan sertlikler, topallıklar gibi klinik semptomla...